Market Performance Snapshot
During the trading session that closed at 09:46 PM Central Europe on Friday, 23 November 2026, the shares of Replimune Group Inc. (REPL) advanced by 2.63 %, reaching a closing price of USD 11.61. The company’s shares are presently circulating at a market capitalisation of USD 1.1 billion, with a total supply of 94.2 million shares. In the 24 hours preceding the close, approximately USD 25.8 million worth of REPL shares changed hands.
Comparing the current performance to the preceding month, REPL has experienced a -12.99 % decline from the close at the end of October 2026. The 200‑day simple moving average stands at USD 9.08, indicating that the recent rally has lifted the stock well above its medium‑term trend. The most recent 52‑week high of USD 16.33 was logged on 2 September 2026, while the 52‑week low of USD 1.50 occurred on 13 April 2026, underscoring a period of considerable volatility for the company.
Context Within the Peer Group
The performance of REPL can be better understood by looking at the recent movements of comparable stocks:
| Company | Ticker | Recent 24‑hr Move | Current Price (USD) | Market Cap (USD) | P/E Ratio |
|---|---|---|---|---|---|
| Coursera | COUR | -1.97 % | 5.08 | 1.3 bn | — |
| Arlo | ARLO | -2.96 % | 13.00 | 1.3 bn | 44.19 |
| First Mid Bancshares | FMBH | +2.76 % | 50.77 | 1.3 bn | 12.24 |
| Navigator | NVGS | -0.94 % | 21.84 | 1.3 bn | 9.83 |
| Nektar Therapeutics | NKTR | +0.99 % | 37.24 | 1.3 bn | — |
While REPL’s rally is modest relative to its peers, it is noteworthy that First Mid Bancshares is the only ticker in the sample that advanced during the same period, suggesting that REPL’s move may reflect sector‑specific momentum rather than a broader market trend.
Recent Corporate Actions
First Mid Bancshares filed a Form 8‑K on 21 October 2026, announcing an amendment to its Registration Rights Agreement with EPL LINCO Trust and PL Generations LLC. The amendment, dated 16 October 2026, extends the registration statement’s effectiveness until 7 August 2027 and designates PL Generations as a permitted transferee, thereby binding it to the agreement’s terms for any shares transferred by the Trust. The filing confirmed that First Mid Bancshares remains listed on the Nasdaq Global Market under the ticker FMBH and reported no other material events or financial details.
Replimune has not disclosed any recent filings of similar nature, indicating that its current trading activity is primarily driven by market sentiment and the broader performance of biotech equities.
Company Overview
Replimune Group Inc. is a clinical‑stage biopharmaceutical firm headquartered in Woburn, Massachusetts. The company’s portfolio focuses on the discovery and development of oncolytic immunotherapies aimed at treating various cancer types. Since its initial public offering on 20 July 2018, Replimune has operated under the Nasdaq ticker REPL and serves customers primarily within the United States.
For further details on Replimune’s research programmes, clinical pipeline, and corporate governance, interested parties may visit the company’s official website at www.replimune.com .
This article provides a factual snapshot of Replimune’s recent market performance and situates it within its peer group, offering readers an accessible perspective on the company’s current standing in the biotech sector.
